A Series in The Lancet Neurology provides state-of-the-art reviews covering clinical and scientific evidence on the four most common genetic subtypes of amyotrophic lateral sclerosis (ALS), caused by ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

A 1975 meeting at the Asilomar Conference Center in Pacific Grove, California, shaped a new safety regime for recombinant DNA ...

Eisai & Biogen announce update on regulatory review of MAA for lecanemab to treat early Alzheimer’s disease by European Commission: Tokyo Wednesday, April 16, 2025, 11:00 Hrs [I ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

Canada Gairdner Awards recognize the world’s most accomplished researchers whose work is improving our understanding of human ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neuroscience and neurodegenerative diseases with a market capitalization of $17.45 billion, finds itself at a ...

MANILA, Philippines — The government’s legal education regulator has ordered the closure of the College of Law of the University of Manila (UM) because of its “dismal performance” in bar ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic, and ...

Biogen had a net margin of 16.87% and a return on equity of 14.98%. On average, analysts forecast that Biogen will post 15.83 earnings per share for the current fiscal year. Insider Buying and ...